Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
NCT02954939

The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis

Led by The University of Hong Kong · Updated on 2024-12-16

50

Participants Needed

1

Research Sites

617 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study investigated the effect of mycophenolate mofetil and cyclosphosphamide on lymphocyte subsets in patients with proliferative lupus nephritis. Patients with biopsy-proven Class III/IV+/-V LN were randomized to received: 1) prednisolone (0.8mg/kg/day) plus CTX (1.5-2mg/kg/d) for 6 months) followed by Azathioprine (AZA) (1-1.5mg/kg/d) maintenance; OR 2) prednisolone (0.8mg/kg/d) plus MMF (1g bd) for 6 months, followed by MMF (tapered according to clinical status) as maintenance. The lymphocyte subsets and serum cytokine profiles will be measured at 4-, 12-, and 24-, 36- and 48 weeks after induction treatment. The lymphocyte subsets and serum cytokine profiles will be compared between the two treatment regimens, and also correlated with subsequent risk of relapse.

CONDITIONS

Official Title

The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with biopsy proven Class III/IV+/-V lupus nephritis (ISN/RPS classification) and active nephritis shown by proteinuria >1g/day and/or serum creatinine rise >15% from baseline, with or without serological reactivation
  • Willing to give informed consent
Not Eligible

You will not qualify if you...

  • Patients who have received calcineurin inhibitors or proliferation signal inhibitors as maintenance immunosuppression in the preceding 3 months
  • Patients who have received biologic therapy (e.g., rituximab, abatacept) in the preceding 12 months
  • Patients who are pregnant or lactating

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Queen Mary Hospital

Hong Kong, Hong Kong

Actively Recruiting

Loading map...

Research Team

D

Desmond YAP, MD (HK)

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

BASIC_SCIENCE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here